Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06271993 · ClinicalTrials.gov registry record · NA
SPT for Sensitization of Collagen Dressing
A NA study, sponsored by Covalon Technologies.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT06271993: Completed NA study, sponsored by Covalon Technologies.
NCT06271993 is a NA study that has completed, run by Covalon Technologies. The registered enrollment target is 27 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06271993, a NA study, has completed, sponsored by Covalon Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to determine the sensitization (contact allergy) potential of the test product ColActive Plus Collagen Matrix Dressing after a skin prick test on the skin of healthy human subjects. The main question it aims to answer is: • Does the product induce any sensitization (contact allergy) after a skin prick using a UniTest PC (pain control) device in healthy human subjects? Participants will have the test product and both positive and negative controls applied, and skin response will be evaluated by an allergist at 15 minutes, 6 hours, and 24-48 hours post-application to see if sensitization occurs.
Primary Outcome
The wheal of each test site will be measured in millimeters. A larger wheal (≥3 mm) is associated with sensitization.
Interventions
- DEVICE ColActivePlus Collagen Matrix Dressing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2024-02-16 |
| Phase | NA |
What the finished NCT06271993 record still lists
NCT06271993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which ColActivePlus Collagen Matrix Dressing is the first listed.
NCT06271993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06271993 about?
NCT06271993 is a clinical study titled "SPT for Sensitization of Collagen Dressing". The goal of this clinical trial is to determine the sensitization (contact allergy) potential of the test product ColActive Plus Collagen Matrix Dressing after a skin prick test on the skin of healthy human subjects. The main question it aims to answer is: • Does the product induce any sensitizatio...
What is the current status of trial NCT06271993?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2024-02-08. Estimated completion is 2024-02-16.
What interventions are being tested in trial NCT06271993?
The interventions under investigation include: ColActivePlus Collagen Matrix Dressing (DEVICE).
Who is sponsoring clinical trial NCT06271993?
This trial is sponsored by Covalon Technologies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06271993's enrollment target sits among peer trials
27 1708th of 2000 higher than 291 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI